Equities analysts predict that DexCom, Inc. (NASDAQ:DXCM) will post earnings of $0.71 per share for the current quarter, Zacks reports. Eleven analysts have issued estimates for DexCom’s earnings, with the lowest EPS estimate coming in at $0.38 and the highest estimate coming in at $0.89. DexCom reported earnings of $0.54 per share during the same quarter last year, which indicates a positive year over year growth rate of 31.5%. The firm is scheduled to issue its next earnings report on Thursday, February 20th.

According to Zacks, analysts expect that DexCom will report full year earnings of $1.42 per share for the current year, with EPS estimates ranging from $1.25 to $1.60. For the next year, analysts anticipate that the company will post earnings of $1.72 per share, with EPS estimates ranging from $1.02 to $2.64. Zacks’ EPS calculations are an average based on a survey of sell-side research firms that that provide coverage for DexCom.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings results on Wednesday, November 6th. The medical device company reported $0.65 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.20 by $0.45. The company had revenue of $396.30 million for the quarter, compared to analysts’ expectations of $348.99 million. DexCom had a positive return on equity of 16.16% and a negative net margin of 12.68%. The firm’s revenue for the quarter was up 48.6% on a year-over-year basis. During the same period in the prior year, the firm earned $0.17 earnings per share.

DXCM has been the topic of a number of recent research reports. ValuEngine downgraded shares of DexCom from a “buy” rating to a “hold” rating in a research report on Wednesday, October 2nd. Piper Jaffray Companies reissued an “overweight” rating on shares of DexCom in a research report on Monday, November 18th. JPMorgan Chase & Co. reissued an “overweight” rating and set a $215.00 price target (up from $190.00) on shares of DexCom in a research report on Thursday, November 7th. Guggenheim raised shares of DexCom from a “neutral” rating to a “buy” rating in a research note on Thursday, November 7th. Finally, Stifel Nicolaus began coverage on shares of DexCom in a report on Tuesday, October 22nd. They issued a “buy” rating and a $190.00 price objective on the stock. Five investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $184.33.

DexCom stock traded down $2.04 on Tuesday, hitting $224.76. 501,003 shares of the stock traded hands, compared to its average volume of 1,020,597. The company has a current ratio of 5.63, a quick ratio of 5.26 and a debt-to-equity ratio of 1.41. The firm has a market cap of $20.76 billion, a P/E ratio of 749.20 and a beta of 0.78. The business’s fifty day simple moving average is $190.15 and its 200 day simple moving average is $159.55. DexCom has a 1 year low of $105.05 and a 1 year high of $232.00.

In other news, Director Mark G. Foletta sold 1,000 shares of the stock in a transaction that occurred on Tuesday, December 3rd. The shares were sold at an average price of $226.80, for a total transaction of $226,800.00. Also, insider Andrew K. Balo sold 9,107 shares of the stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $151.56, for a total transaction of $1,380,256.92. The disclosure for this sale can be found here. In the last ninety days, insiders sold 88,459 shares of company stock valued at $14,293,477. 1.80% of the stock is owned by insiders.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Janney Montgomery Scott LLC increased its holdings in shares of DexCom by 23.6% in the 2nd quarter. Janney Montgomery Scott LLC now owns 12,360 shares of the medical device company’s stock worth $1,852,000 after purchasing an additional 2,357 shares in the last quarter. Oppenheimer & Co. Inc. increased its holdings in DexCom by 20.1% in the 3rd quarter. Oppenheimer & Co. Inc. now owns 3,575 shares of the medical device company’s stock worth $534,000 after buying an additional 599 shares in the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. increased its holdings in DexCom by 14.1% in the 2nd quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 12,320 shares of the medical device company’s stock worth $1,846,000 after buying an additional 1,519 shares in the last quarter. United Capital Financial Advisers LLC raised its position in DexCom by 20.6% in the 2nd quarter. United Capital Financial Advisers LLC now owns 3,161 shares of the medical device company’s stock worth $474,000 after buying an additional 539 shares during the last quarter. Finally, MayTech Global Investments LLC raised its position in DexCom by 2.1% in the 2nd quarter. MayTech Global Investments LLC now owns 45,365 shares of the medical device company’s stock worth $6,797,000 after buying an additional 934 shares during the last quarter. Institutional investors own 98.20% of the company’s stock.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.

Read More: How to invest using market indexes

Get a free copy of the Zacks research report on DexCom (DXCM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.